Abstract
Neurodegenerative disorders are responsible for malfunctioning of brain and peripheral nervous system. The therapeutic drugs that are commonly utilized for the treatment of these disorders are not able to pass through the blood–brain barrier (BBB) as it permits passage of specific nutrients which are helpful for growth. Thus, nanotechnology (NT) can be very much valuable in solving this problem as there are different forms of nanomaterials that can act as efficient drug delivery systems and help in crossing the BBB and providing effective treatment for neurodegenerative disorders like Alzheimer’s disease, Parkinson’s disease, and many more. Thus, in this chapter, we tried to conglomerate all the recent developments related to neurodegenerative disorders and also provide a brief overview about the importance of nanotechnology in varied biomedical applications.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Akinc A, Battaglia G (2013) Exploiting endocytosis for nanomedicines. Cold Spring Harb Perspect Biol 5(11):a016980. https://doi.org/10.1101/cshperspect.a016980
Agarwal S (2006). Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis. J Exp Med; 203:1007–1019. [PubMed: 16585265]
Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Rosenberg SA (2005) Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 23(25):6043–6053. https://doi.org/10.1200/JCO.2005.06.205
Broadwell RD, Sofroniew MV (1993). Serum proteins bypass the blood–brain fluid barriers for extracellular entry to the central nervous system. Exp Neurol; 120:245–263. [PubMed: 8491281]
Bocti C (2006). Topographical patterns of lobar atrophy in frontotemporal dementia and Alzheimer’s disease. Dement Geriatr Cogn Disord;21:364–372. [PubMed: 16534206]
Bencsik AA, Debeer SOS, Baron TGM (2005) An alternative pretreatment procedure in animal transmissible spongiform encephalopathies diagnosis using PrPsc immunohistochemistry. Journal of Histochemistry & Cytochemistry 53(10):1199–1202. https://doi.org/10.1369/jhc.5C6703.2005
Banks WA (2002). Passage of amyloid beta protein antibody across the blood–brain barrier in a mouse model of Alzheimer’s disease. Peptides; 23: 2223–2226. [PubMed: 12535702]
Cui WW, Low SE, Hirata H, Saint-Amant L, Geisler R, Hume RI, Kuwada JY (2005) The zebrafish shocked gene encodes a glycine transporter and is essential for the function of early neural circuits in the CNS. J Neurosci Off J Soc Neurosci 25(28):6610–6620
Davis DS, Ashby PE, McCale KL, McQuain JA, Wine JM (2005) The effectiveness of 3 stretching techniques on hamstring flexibility using consistent stretching parameters. J Strength Cond Res 19(1):27–32
Duncan R (2003). The dawning era of polymer therapeutics. Nat Rev Drug Discov. [PubMed: 12750738], 2, 347
Dhib-Jalbut S (2006) Neurodegeneration and neuroprotection in multiple sclerosis and other neurodegenerative diseases. J Neuroimmunol;176:198–215. [PubMed: 16983747]
Flachenecker P. (2006) Epidemiology of neuroimmunological diseases. J Neurol;253:v2–v8. [PubMed: 16998750]
Gaillard PJ, Visser CC, de Boer AG (2005) Targeted delivery across the blood–brain barrier. Expert Opin Drug Deliv; 2:299–309. [PubMed: 16296755]
Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA (2005) Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A 102(7):2273–2276. https://doi.org/10.1073/pnas.0409336102
Gobbi G, Bambico FR, Mangieri R, Bortolato M, Campolongo P, Solinas M, Piomelli D (2005) Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 102(51):18620–18625. https://doi.org/10.1073/pnas.0509591102
Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA (2008) Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv 5(2):155–174. https://doi.org/10.1517/17425247.5.2.155
Härtig W, Mages B, Aleithe S, Nitzsche B, Altmann S, Barthel H et al (2017) Damaged neocortical Perineuronal nets due to experimental focal cerebral ischemia in mice, rats and sheep. Front Integr Neurosci 11:15. https://doi.org/10.3389/fnint.2017.00015
Han G, Gable K, Yan L, Allen MJ, Wilson WH, Moitra P, Harmon JM, Dunn TM (2006) Expression of a novel marine viral single-chain serine palmitoyltransferase and construction of yeast and mammalian single-chain chimera. J Biol Chem 281(52):39935–39942
Huang X, Lin J, Demner-Fushman D (2006) Evaluation of PICO as a knowledge representation for clinical questions. AMIA … annual symposium proceedings. AMIA Symposium 2006:359–363
Khachaturian ZS (2006) Diagnosis of Alzheimer’s disease: two-decades of progress. J Alzheimers Dis 2006;9:409–415. [PubMed: 16914879]
Kim SU (2007) Genetically engineered human neural stem cells for brain repair in neurological diseases. Brain and Development;29:193–201. [PubMed: 17303360]
Kingsley JD (2006) Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmunol Pharmacol 1:340–350
Lehericy S (2007) Magnetic resonance imaging of Alzheimer’s disease. Eur Radiol, 17:347–362. [PubMed: 16865367]
Langer R (2001). Drug delivery. Drugs on target Science; 293:58–59. [PubMed: 11441170]
Kogan MJ, Bastus NG, Amigo R, Grillo-Bosch D, Araya E, Turiel A, Labarta A, Giralt E, Puntes VF (2006) Nanoparticle-mediated local and remote manipulation of protein aggregation. Nano Lett 6(1):110–115. https://doi.org/10.1021/nl0516862
Neumann H (2006). Microglia: a cellular vehicle for CNS gene therapy. J Clin Invest; 116:2857–2860. [PubMed: 17080190]
Prinster A (2006) Grey matter loss in relapsing-remitting multiple sclerosis: a voxel-based morphometry study. NeuroImage; 29:859–867. [PubMed: 16203159]
Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2(1):3–14. https://doi.org/10.1602/neurorx.2.1.3
Robichaud AJ (2006) Approaches to palliative therapies for Alzheimer’s disease. Curr Top Med Chem; 6: 553–568. [PubMed: 16712491]
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK (2015) Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43(7):e47. https://doi.org/10.1093/nar/gkv007
Ramanathan S, Archunan G, Sivakumar M, Tamil Selvan S, Fred AL, Kumar S, Padmanabhan P (2018) Theranostic applications of nanoparticles in neurodegenerative disorders. Int J Nanomed 13:5561–5576. https://doi.org/10.2147/IJN.S149022
Serra P, Santamaria P (2018) Nanoparticle-based approaches to immune tolerance for the treatment of autoimmune diseases. Eur J Immunol 48:751–756. https://doi.org/10.1002/eji.201747059
Shyam S, Arshad F, Abdul Ghani R, Wahab NA, Safii NS, Nisak MY, Kamaruddin NA (2013) Low glycaemic index diets improve glucose tolerance and body weight in women with previous history of gestational diabetes: a six months randomized trial. Nutr J 12:68. https://doi.org/10.1186/1475-2891-12-68
Silva GA (2006). Neuroscience nanotechnology: progress, opportunities and challenges. Nat Rev Neurosci;7:65–74. [PubMed: 16371951]
Smith MW, Gumbleton M (2006) Endocytosis at the blood–brain barrier: from basic understanding to drug delivery strategies. J Drug Target;14:191–214. [PubMed: 16777679]
Sonvico F, Clementino A, Buttini F, Colombo G, Pescina S, Stanisçuaski Guterres S, Nicoli S (2018) Surface-modified Nanocarriers for nose-to-brain delivery: from bioadhesion to targeting. Pharmaceutics 10(1):34. https://doi.org/10.3390/pharmaceutics10010034
Stupp R, Brada M, van den Bent MJ, Tonn JC, Pentheroudakis G, ESMO Guidelines Working Group (2014) High-grade glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 25(3):93–101. https://doi.org/10.1093/annonc/mdu050
Schrag A, Quinn NP, Ben-Shlomo Y (2006) Heterogeneity of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2006;77:275–276. [PubMed: 16421140]
Saltzman WM (1999) Intracranial delivery of recombinant nerve growth factor: release kinetics and protein distribution for three delivery systems. Pharm Res 16:232–240. [PubMed: 10100308]
Simpkins JW, Bodor N (2014) Brain-targeted delivery of dopamine using are dox-based chemical delivery system. Adv Drug Deliv Rev 14:243–249
Tyler CM, Federoff HJ (2006) CNS gene therapy and a nexus of complexity: systems and biology at a crossroads. Cell Transplant;15:267–273. [PubMed: 16719061]
Teleanu DM, Negut I, Grumezescu V, Grumezescu AM, Teleanu RI (2019) Nanomaterials for drug delivery to the central nervous system. Nanomaterials (Basel Switzerland) 9(3):371. https://doi.org/10.3390/nano9030371
Trapani S, Micheli A, Grisolia F, Resti M, Chiappini E, Falcini F, De Martino M (2005) Henoch Schonlein purpura in childhood: epidemiological and clinical analysis of 150 cases over a 5-year period and review of literature. Semin Arthritis Rheum 3(35):143–153. https://doi.org/10.1016/j.semarthrit.2005.08.007
Tamai I, Tsuji A (2000). Transporter-mediated permeation of drugs across the blood–brain barrier. J Pharm Sci; 89:1371–1388. [PubMed: 11015683]
Vinogradov, S., Fisher, M., & de Villers-Sidani, E. (2012). Cognitive training for impaired neural systems in neuropsychiatric illness. Neuropsychopharmacology, 37(1), 43–76. doi:https://doi.org/10.1038/npp.2011.251
Woods SC (2003) Insulin and the blood–brain barrier. Curr Pharm Des; 9:795–800. [PubMed: 12678878]
Wang X, Bo J, Bridges T, Dugan KD, Pan TC, Chodosh LA, Montell DJ (2006) Analysis of cell migration using whole-genome expression profiling of migratory cells in the Drosophila ovary. Dev Cell 10(4):483–495
Wang L, Zhao W, Tan W (2008) Bioconjugated silica nanoparticles: development and applications. Nano Res 1:99. https://doi.org/10.1007/s12274-008-8018-3
Weissig V (2006). Liposomes and liposome-like vesicles for drug and DNA delivery to mitochondria. J Liposome Res; 16:249–264. [PubMed: 16952879]
Acknowledgement
The author is thankful to GITAM University, Visakhapatnam, Andhra Pradesh, India, for providing financial support and facilities to carry out this review.
Conflicts of Interest
The author has declared that no conflicts of interest exist.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rahaman, S.T. (2019). The Role of Nanomedicine in the Treatment of Neurodegenerative Disorders. In: Rai, M., Yadav, A. (eds) Nanobiotechnology in Neurodegenerative Diseases. Springer, Cham. https://doi.org/10.1007/978-3-030-30930-5_3
Download citation
DOI: https://doi.org/10.1007/978-3-030-30930-5_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-30929-9
Online ISBN: 978-3-030-30930-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)